Research

Simplification of antiretroviral treatment will improve the quality of life of HIV patients

A trial carried out entirely in Catalonia has shown that therapy with dolutegravir plus lamivudine has an efficacy similar to that of triple therapy. It does not cause resistance or have any side effects; it is cheaper and offers less risk of long-term toxicity than triple therapies. 

Dr. Esteban Martínez, Dra. Elisa de Lazzari and Dr. José Luis Blanco. Hospital Clínic de Barcelona/IDIBAPS Infectious Diseases Service Research Group

Related contents